Compare EFSCP & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Enterprise Financial Services Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of 5% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Current Price
| Metric | EFSCP | CADL |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | 1256 | 55 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 357.4M |
| IPO Year | N/A | 2021 |
| Metric | EFSCP | CADL |
|---|---|---|
| Price | $19.77 | $4.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.71 |
| AVG Volume (30 Days) | 1.4K | ★ 1.2M |
| Earning Date | N/A | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.20 | $4.25 |
| 52 Week High | $20.95 | $7.24 |
| Indicator | EFSCP | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 41.91 |
| Support Level | $19.49 | $4.58 |
| Resistance Level | $20.78 | $5.42 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 34.56 | 22.96 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.